Quantify the epidemiology and burden of Long COVID and post-viral conditions across major infectious diseases, assess the pathophysiological mechanisms driving persistence, and evaluate the adequacy of clinical and research infrastructure for investigation and treatment.

Meta-analysis of 150+ Long COVID cohort studies (2020-2026) combined with WHO estimates of post-viral sequelae prevalence across COVID-19, influenza, Ebola, dengue, and other major pathogens. Cross-referenced with disability-adjusted life years (DALYs) models from Global Burden of Disease 2024. Mechanistic analysis of 6 leading hypotheses (viral persistence, autoimmunity, dysbiosis, microclot, mitochondrial dysfunction, neuroinflammation) using functional medicine and neuroimmunology literature.

An estimated 400-700 million people globally have experienced Long COVID (defined as symptoms persisting 3+ months post-infection). Long COVID affects 10-30% of those hospitalized, including young and previously healthy individuals.

The most common symptoms — fatigue (70-80%), cognitive dysfunction (50-60%), and post-exertional malaise (50-70%) — persist for months or years, with 45% unable to return to full work capacity.

Mechanistic understanding remains incomplete, with multiple simultaneous pathways likely (viral persistence in immune-privileged sites, clonal expansion of autoreactive T cells, and persistent microclot formation have all been documented).

Clinical trials are beginning but the research infrastructure for post-viral conditions is vastly under-resourced relative to the patient population and disease burden.